ProteoWise
Automated benchtop platform for multiplex protein analysis, making proteomics faster, cheaper, and easier.
Website: https://proteowise.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | ProteoWise [Crunchbase] |
| Tagline | Automated benchtop platform for multiplex protein analysis, making proteomics faster, cheaper, and easier [ProteoWise] |
| Headquarters | New Haven, United States [Crunchbase] |
| Founded | 2018 [Crunchbase] |
| Stage | Series C [Crunchbase] |
| Business model | Hardware + Software [Crunchbase] |
| Industry | Healthtech [Crunchbase] |
| Technology type | Biotech / Life Sciences [Crunchbase] |
| Geography | North America [Crunchbase] |
| Growth profile | Venture Scale [Crunchbase] |
| Founding team | Academic Spinout [ProteoWise, Unknown] |
| Funding label | $10M+ [CB Insights] |
| Total disclosed | ~$15,270,000 [CB Insights] |
Links
Publicly reported
- Website: https://proteowise.com/
- HyperBlot: https://proteowise.com/
- About Us: https://proteowise.com/about-us/
- Our Technology: https://proteowise.com/our-technology/
- Our Team: https://proteowise.com/our-team/
- Contact: https://proteowise.com/contact-us/
Summary and Signal
PUBLIC ProteoWise is building an automated benchtop platform for multiplex protein analysis, and it merits investor attention now because the company has moved from platform description to a first named in-field beta deployment at Yale School of Medicine's Department of Neurology in December 2024 [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown]. Founded in 2018 in New Haven as a Yale spinout, the company sits in a part of life-science tooling where workflow friction remains high and where even modest gains in throughput, sample efficiency, and reproducibility can matter to research labs and biopharma users [Crunchbase, Unknown] [ProteoWise, Unknown].
The product, Hyperblot, is described by the company as an integrated system of instrument, reagents, cartridge, and analysis software, built around an "immortalized membrane" that captures and covalently binds proteins so multiple targets can be analyzed from one sample [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown] [RocketReach, 2026]. That differentiation is strategically sensible if it holds up in routine lab use, because the commercial pitch is not a new protein target or assay alone, but a simpler multiplex workflow that compresses a labor-intensive Western blot process into a more automated readout [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024].
The founding team is also part of the story. Erik Gunther and Mikhail Kostylev are tied to the underlying Yale research base, while Stephen M. Strittmatter brings senior academic credibility from Yale School of Medicine and a record of prior biotech company formation, according to Yale, Crunchbase, and company materials [Yale School of Medicine, 2026] [Crunchbase, 2026] [ProteoWise, Unknown].
On capital formation, public databases indicate disclosed funding of about $15.27 million across six rounds, though round-level reporting is inconsistent enough that the figure should be treated as reported rather than fully reconciled [CB Insights] [Crunchbase, Unknown] [Tracxn, Unknown]. The investor list includes Connecticut Innovations, Cultivation Capital, Creator Capital, Foothill Ventures, Taihill Venture, Co-Win Ventures, UniWill Ventures, and the National Institute on Aging, and the business model appears to be a hardware plus software sale into research settings rather than a pure tools-consumables model at this stage [CB Insights] [Tracxn, Unknown] [ProteoWise, Unknown].
Over the next 12 to 18 months, the key watchpoints are straightforward: whether the Yale beta placement turns into broader external adoption, whether additional named deployments or partnerships emerge beyond company-distributed announcements, and whether ProteoWise can reduce the current evidence gap between technical promise and independently verified commercial traction [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown]. For investors, this remains an interesting but still early instrumentation bet where the upside rests on workflow change, and the diligence burden rests on proving repeatability, customer demand, and sales motion outside the founding network.
No independent source found -- This section relies materially on company materials and company-distributed announcements, with partial corroboration from Crunchbase, CB Insights, Tracxn, Yale School of Medicine, and RocketReach.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series C |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | $10M+ total disclosed, reported at about $15.27M [CB Insights] [Crunchbase, Unknown] |
Company Overview
PUBLIC
ProteoWise is a New Haven, Connecticut company founded in 2018, with roots that are clearly tied to Yale rather than to a stand-alone commercial lab operation [Crunchbase] [ProteoWise]. The company presents itself as a Yale-founded team building Hyperblot, a benchtop system for multiplex protein analysis, and public profiles categorize the business as a hardware-plus-software life sciences company at the Series C stage [ProteoWise] [Crunchbase].
The founding bench appears academically anchored. Public materials name Erik Gunther, Mikhail Kostylev, and Stephen M. Strittmatter as founders, while the company site describes the team as scientists from Yale University and Crunchbase records Strittmatter and Kostylev as co-founders on their respective profiles [ProteoWise] [Crunchbase].
The public milestone trail is still short, but it is enough to show a progression from company formation to early field use. Crunchbase records financing activity beginning in March 2020 and additional reported rounds in April 2021 and December 2024, while the company announced in December 2024 that the first in-field beta Hyperblot system had been deployed at Yale School of Medicine's Department of Neurology [Crunchbase] [PRWeb / PRNewswire-PRWeb, December 2024]. That sequence matters because it places ProteoWise in the transition from platform development to external deployment, even if public sources do not yet establish broad commercial rollout [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise].
One source, partially checked -- Company identity, founding year, headquarters, and founder names are corroborated by Crunchbase and the company website, but milestone chronology beyond formation relies partly on company-announced deployment details.
The Product and the Stack
MIXED
The product story is fairly crisp even if the underlying evidence is still thin. ProteoWise describes Hyperblot as an automated benchtop platform for multiplex protein analysis, built to condense a labor-intensive Western blot style workflow into a simpler instrument-led process [ProteoWise] [PRWeb / PRNewswire-PRWeb, December 2024]. In the company’s public materials and December 2024 deployment announcement, Hyperblot is described as a system that combines an instrument, reagents, a cartridge, and data-analysis software, with the user flow framed as loading samples, selecting analytes, pressing start, and receiving quantified multiplex proteomic data from a single experiment [ProteoWise] [PRWeb / PRNewswire-PRWeb, December 2024].
The technical claim that matters most is the membrane architecture. ProteoWise says Hyperblot uses an "immortalized membrane" that captures and covalently binds proteins, which the company says allows multiple protein targets, and in one third-party profile hundreds of targets, to be analyzed from the same sample [ProteoWise] [RocketReach, 2026]. That positioning is directionally attractive because it speaks to the practical constraints of proteomics labs, sample volume, throughput, and workflow complexity, but investors should read those advantages as company-framed performance claims rather than independently benchmarked comparisons at this stage [ProteoWise] [PRWeb / PRNewswire-PRWeb, December 2024].
Public validation has started to move from concept to field use, though only modestly. ProteoWise announced in December 2024 that it had deployed its first in-field beta Hyperblot system at Yale School of Medicine's Department of Neurology, which is the clearest public sign that the platform has progressed beyond internal development and into external laboratory use [PRWeb / PRNewswire-PRWeb, December 2024]. The same public materials point to target users in academic labs, biopharma research, and clinical discovery settings, but there is not yet a broad public record of commercial deployments, peer-reviewed performance data, or third-party workflow benchmarks that would let an outside investor underwrite technical differentiation with high confidence [ProteoWise] [Yahoo Finance, December 2024].
No independent source found -- Core product and performance descriptions rely primarily on company materials and a company-distributed press announcement, with limited third-party corroboration.
The Market They Are Entering
PUBLIC
The market matters now because proteomics remains information-rich but workflow-constrained, and ProteoWise is trying to sell into that gap rather than invent demand from scratch [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024].
Public evidence on market size is thin, and there is no named third-party TAM, SAM, or SOM figure in the sourced record for ProteoWise itself. That limits precision. Still, the company is clearly positioned against a familiar bottleneck, conventional Western blot and related protein-analysis workflows that are slower, lower-throughput, and more manual than many genomics-era lab teams now expect [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024].
Demand drivers in the public record are practical rather than speculative. ProteoWise describes Hyperblot as a benchtop system for multiplex protein analysis that combines an instrument, reagents, cartridge, and software, with the promise of quantified data from a single run and reduced workflow complexity [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024]. If that operating claim holds in routine use, the product would appeal most where sample volume is limited, antibody panels matter, and labor time is expensive, which fits the company-described user set of academic labs, biopharma researchers, and clinical-discovery groups [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024].
The adjacent markets are easier to identify than the core market size. ProteoWise sits near Western blot instrumentation and consumables, multiplex immunoassays, translational proteomics tools, and broader life-science lab automation [ProteoWise, Unknown] [RocketReach, 2026]. That adjacency cuts both ways. It expands the pool of substitute budgets, but it also means buying decisions may be compared against existing assay platforms, service providers, and incremental automation upgrades rather than treated as a greenfield software purchase.
Regulatory and macro forces appear indirect but still relevant. There is no public evidence here of an FDA pathway or a regulated clinical-diagnostics positioning; the available material reads as research-use and discovery-oriented rather than near-term clinical deployment [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown]. The more important macro factors are likely budget discipline in academic and biotech labs, the willingness of labs to adopt integrated instrument-consumable workflows, and continued pressure to generate more data from smaller samples, all of which are consistent with the use case ProteoWise is describing, though not independently quantified in the source set [ProteoWise, Unknown] [CB Insights].
| Market lens | Publicly supported read | Evidence |
|---|---|---|
| Core problem area | Protein analysis workflows remain sufficiently cumbersome that ProteoWise frames speed, throughput, cost, and simplicity as the product wedge | [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024] |
| Initial buyer groups | Academic laboratories, biopharmaceutical researchers, and clinical-discovery groups are the named target users in the sourced material | [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024] |
| Closest budget adjacency | Western blot alternatives, multiplex proteomics tools, and lab automation appear to be the nearest spend categories | [ProteoWise, Unknown] [RocketReach, 2026] |
| Regulatory posture in public sources | Research and discovery use is evidenced; clinical regulatory positioning is not established in the public record provided | [PRWeb / PRNewswire-PRWeb, December 2024] |
The table points to a real market need, but not yet to a well-bounded market model. At this stage, the investment question is less about headline TAM and more about whether ProteoWise can convert a known lab pain point into a repeatable instrument-plus-consumables buying motion.
No independent source found -- This section relies primarily on company materials and one company-distributed announcement, with no named third-party market-sizing report in the source set.
The Competitive Field
MIXED ProteoWise appears to be positioning Hyperblot less against a single named startup rival and more against the entrenched Western blot workflow that still dominates routine protein analysis in many research labs, a useful wedge if the company can turn automation claims into repeat lab adoption [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024].
The public record here is thinner than an institutional reader would want, and that matters because competitive mapping in proteomics depends heavily on named peers, installed base, and workflow fit. In the available source set, ProteoWise is described as offering an automated benchtop platform for multiplex protein analysis, with an instrument, reagents, cartridge, and software stack aimed at reducing the time, sample volume, and workflow complexity associated with conventional Western blots [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024] [Yahoo Finance, December 2024]. What is missing is a source-grounded list of direct competitors, so the cleanest public reading is that the company is attacking a method category first, not yet a clearly documented peer set.
That leaves the competitive map in three practical segments. First are incumbent lab methods, especially Western blot based protein analysis, which ProteoWise repeatedly cites as the workflow it is trying to simplify and compress into a more automated process [ProteoWise, Unknown] [PRWeb / PRNewswire-PRWeb, December 2024]. Second are adjacent substitutes inside academic and biopharma research, where labs can choose broader proteomics workflows or stay with existing assay stacks rather than adopt a new benchtop system, although the provided sources do not name those vendors directly [CB Insights]. Third are internal do-it-yourself workflows in research settings, which often persist not because they are better, but because they are already validated in the lab and paid for. ProteoWise's challenge is therefore not only technical substitution but behavior change.
The edge that can be defended today is narrower and more credible than a broad platform claim. ProteoWise has a Yale spinout origin, a founding team with direct neuroscience and academic research credentials, and at least one named beta deployment inside Yale School of Medicine's Department of Neurology as of December 2024 [ProteoWise, Unknown] [Yale School of Medicine, 2026] [PRWeb / PRNewswire-PRWeb, December 2024] [Crunchbase, 2026]. For an early commercial instrument company, that combination can matter because early buyers often underwrite risk based on trust in the scientists and proximity to reference users. The durability of that edge is conditional. Academic credibility and founder expertise help open doors, but they are perishable if they do not convert into reproducible performance data, published validation, and a broader installed base beyond the originating institution.
The company is more exposed on distribution and category proof than on concept. No public source here verifies a scaled commercial channel, a list of paying customers, or a broad set of field deployments beyond the first Yale beta announcement [PRWeb / PRNewswire-PRWeb, December 2024]. The funding record also looks fragmented across databases, with CB Insights reporting $15.27 million across six rounds while other databases cited in the research disagree on totals and round treatment, which makes it harder to judge how much capital ProteoWise has to outlast longer instrument adoption cycles [CB Insights] [Crunchbase, Unknown] [Tracxn, Unknown]. In practice, the strongest competitor to ProteoWise over the next 18 months may not be a named startup at all, but the installed status quo inside labs that already know how to generate acceptable results from legacy workflows.
The most plausible 18 month scenario is therefore a split outcome shaped by validation. ProteoWise is the likely winner if Hyperblot can turn the Yale beta and related early collaborations into cited application data, a small but visible set of reference accounts, and clearer proof that the workflow produces comparable or better results with less labor [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown]. Western blot based incumbent practice is the likely loser if that proof emerges in routine use cases where speed, multiplexing, and lower sample burden matter. ProteoWise is the likely loser if adoption remains concentrated in founder-adjacent academic settings and the company cannot show that external labs will change established workflows without heavy hand-holding. That is a common failure mode in research tools, and the current public evidence does not yet rule it out.
One source, partially checked -- Based primarily on company materials and one December 2024 deployment announcement, with partial corroboration from Crunchbase and Yale-affiliated profiles, but no named direct competitors confirmed in the provided public sources.
Opportunity
PUBLIC
The prize here is not a marginally better lab tool, but a chance to become a workflow standard for protein analysis at the bench if ProteoWise can turn its first beta deployment into repeatable adoption across research labs and biopharma discovery settings [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown].
The headline opportunity is straightforward. ProteoWise is trying to replace a slow, labor-intensive protein analysis workflow with an automated benchtop system that combines instrument, reagents, cartridge, and analysis software, then returns quantified multiplex data from a single experiment [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown]. That outcome is still early, but it is not purely aspirational: the company has a named product, a clear initial use case anchored in Western blot replacement, a Yale-origin technical story, and a first in-field beta system deployed at Yale School of Medicine's Department of Neurology in December 2024 [PRWeb / PRNewswire-PRWeb, December 2024] [Crunchbase, Unknown]. In practice, that means the company has crossed at least one important line from concept to external lab use, which is often the gating step for instrumentation companies that need application proof before broader commercial scale [PRWeb / PRNewswire-PRWeb, December 2024].
The most credible paths to scale are visible, even if the evidence base is still thin.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Academic core-facility wedge | Hyperblot becomes a preferred instrument for university and medical-school labs that need higher-throughput multiplex protein analysis | The first beta deployment at Yale converts into reference data, repeat installations, and publication-driven credibility [PRWeb / PRNewswire-PRWeb, December 2024] | ProteoWise is a Yale spinout, its first named deployment is inside Yale School of Medicine, and the product is framed around simplifying a familiar workflow rather than asking labs to adopt an entirely new biological paradigm [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown] |
| Biopharma discovery workflow | The platform moves from academic validation into drug-discovery and translational research groups that want faster protein readouts with lower sample burden | Partnerships such as the June 2024 Nominatech announcement broaden assay-development and discovery use cases, if they convert into recurring instrument or consumables demand [ProteoWise, Unknown] | Public company descriptions already identify biopharmaceutical researchers and clinical-discovery groups as target users, which suggests the go-to-market map is broader than academia even if customer proof remains early [ProteoWise, Unknown] [Yahoo Finance, December 2024] |
| Consumables-and-software stack | ProteoWise evolves from a one-time instrument sale into a recurring revenue model tied to cartridges, reagents, and analysis workflows | More installed systems create repeat demand for assay consumables and normalize use of the software layer bundled with Hyperblot [PRWeb / PRNewswire-PRWeb, December 2024] | The product is described as a full stack, instrument plus reagents, cartridge, and data-analysis software, which usually creates more than one monetization surface if utilization rises [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown] |
What compounding looks like is less about a classic consumer network effect and more about laboratory workflow lock-in. If Hyperblot produces reliable multiplex protein data with less manual work, each installed system could reinforce the next sale through internal lab champions, shared protocols, assay familiarity, and recurring reagent purchases tied to that installed base [PRWeb / PRNewswire-PRWeb, December 2024] [ProteoWise, Unknown]. The company's early signals matter here: a first in-field deployment shows external use, and the product architecture already spans hardware, consumables, and software, which is the combination that can make replacement harder once a lab has validated its workflow on the system [PRWeb / PRNewswire-PRWeb, December 2024]. The moat, if one forms, would likely come from validated assays, switching costs in established experimental workflows, and proprietary know-how around the company's "immortalized membrane" approach, rather than from distribution scale alone [ProteoWise, Unknown] [RocketReach, 2026].
The size of the win is harder to quantify from the current public record because no credible market-sizing source or directly named public comparable appears in the evidence set. Still, the disclosed funding base offers a rough boundary on ambition: CB Insights reports $15.27 million raised across six rounds, which is consistent with a company still in early commercial formation rather than broad market saturation [CB Insights]. If the academic-core scenario or biopharma-workflow scenario plays out, the outcome could be a strategic-instrumentation platform with meaningful value to larger life science tools buyers or growth investors, particularly if recurring consumables usage proves durable (scenario, not a forecast) [CB Insights] [PRWeb / PRNewswire-PRWeb, December 2024]. The public evidence supports real upside from workflow standardization, but it does not yet support a precise valuation case.
No independent source found -- This section relies materially on company descriptions and a company-distributed PR announcement, with limited independent corroboration beyond database profiles.
Sources
Publicly reported
[Crunchbase, 2026] ProteoWise - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/proteowise
[ProteoWise] ProteoWise | https://proteowise.com/
[PRWeb / PRNewswire-PRWeb, December 2024] ProteoWise Deploys First Hyperblot™ System, Bringing the Power of Proteomics to Every Lab Bench | https://www.prweb.com/releases/proteowise-deploys-first-hyperblottm-system-bringing-the-power-of-proteomics-to-every-lab-bench-302332274.html
[RocketReach, 2026] ProteoWise Information | https://rocketreach.co/proteowise-profile_b439bf76c18a0752
[Yale School of Medicine, 2026] Stephen Strittmatter, MD, PhD, AB | Yale School of Medicine | https://medicine.yale.edu/profile/stephen-strittmatter/
[CB Insights] ProteoWise - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/proteowise
[Tracxn] ProteoWise - 2026 Funding Rounds & List of Investors - Tracxn | https://tracxn.com/d/companies/proteowise/__hPDDbdFSUchCi91UNusz055ZqGJvMIn0wmzUIZcrVRE/funding-and-investors
[Yahoo Finance, December 2024] ProteoWise Deploys First HyperblotTM System, Bringing the Power of Proteomics to Every Lab Bench | https://finance.yahoo.com/news/proteowise-deploys-first-hyperblottm-system-140000663.html
Articles about ProteoWise
- Hyperblot's First Beta Deployment Is Inside a Yale Neurology Lab — The Yale spinout's Hyperblot system, now in its first beta at the university, aims to replace a manual, decades-old protein analysis technique.